We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01238809
First Posted: November 11, 2010
Last Update Posted: June 8, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this study is to assess in general population low-dose aspirin and gastroprotective agent compliance and reasons for bad compliance

Condition
Self-administered Questionnaire to Patients

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • low-dose aspirin and gastroprotective treatment compliance (Girerd questionnaire: a 6-item self-administered and validated questionnaire to evaluate adherence to treatments) [ Time Frame: One month ]

Estimated Enrollment: 7300
Study Start Date: June 2011
Estimated Study Completion Date: July 2011
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Community sample
Criteria

Inclusion Criteria:

  • French people > 60 years old, part of Kantar Health Access Sant� panel

Exclusion Criteria: -

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01238809


Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Mrs Genevieve BONNELYE KantarHealth - France
  More Information

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT01238809     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2010/1
First Submitted: November 9, 2010
First Posted: November 11, 2010
Last Update Posted: June 8, 2011
Last Verified: June 2011

Keywords provided by AstraZeneca:
Compliance
France

Additional relevant MeSH terms:
Aspirin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics